In this section

ICR publications

ICR ImmNet publications feed

Browse all ICR publications

Novel Treatment Approaches in Recurrent/Metastatic Squamous Head and Neck Cancer.

01 February 2026
JADE: phase 3 study of sequential dostarlimab post chemoradiotherapy in patients with locally advanced unresected HNSCC.

30 January 2026
Cutaneous toxicities in patients with metastatic uveal melanoma receiving tebentafusp: a retrospective review. The experience of a single large specialist institution.

27 January 2026
Unhooking the Hook: Optimization of the Aurora A Targeting PROTAC JB170 to CCT400028, an In Vitro Degrader Chemical Probe.

22 January 2026
Community benchmarking and evaluation of human unannotated microprotein detection by mass spectrometry based proteomics.

21 January 2026
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors.

01 January 2026
Updates on radiotherapy-immunotherapy combinations: Proceedings of 8th Annual ImmunoRad Conference.

31 December 2025
Updates on radiotherapy-immunotherapy combinations: Proceedings of 8th Annual ImmunoRad Conference.

31 December 2025
The accessory type III secretion system effectors collectively shape intestinal inflammatory infection outcomes.

31 December 2025
Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7th immunorad conference.

31 December 2025
INDUCE-3: A randomized Phase II/III study of first-line feladilimab plus pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma.

22 December 2025
Somatic evolution following cancer treatment in normal tissue.

10 December 2025